ESMO-Preceptorship-Metastatic and Kidney Cancer-2022-1000x250-july

Start date: 11 Jul 2022
End date: 12 Jul 2022
Location: Lugano, Switzerland

Learning objectives

To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
To learn about advances in treatment and novel targets in bladder and kidney cancer

Accreditation

The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

Laurence Albiges, France
Viktor Grünwald, Germany

Learning objectives

Accreditation

Co-Chairs

Supported by

You may also be interested in...